Abbott Q3 2026 sales up 14.5% reported, 7.0% comparable; adjusted EPS $1.42; FY guidance tightened to $5.50-$5.55

ABBOTT LABORATORIES

Total company third-quarter sales were $13.01 billion, up 14.5% reported and 7.0% comparable, with U.S. sales up 28.0% to $5.50 billion.
GAAP diluted EPS was $0.53 versus adjusted diluted EPS of $1.42; full-year 2026 adjusted EPS guidance reaffirmed at midpoint and narrowed to $5.50-$5.55.
Diagnostics sales jumped 46.7% reported to $3.31 billion, driven by the March 23, 2026 Exact Sciences acquisition and 13.8% comparable Cancer Diagnostics growth.
Medical Devices sales rose 6.9% to $5.83 billion, led by 15.0% growth in Electrophysiology; Diabetes Care CGM sales grew 7.3% reported.
Abbott cited FDA approval of Libre Duo, CE Mark for Amulet 360, FDA approval of TactiFlex Duo and launch of SimpleScreen CRC; Q4 adjusted EPS guided to $1.62-$1.67.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.